Interpace Biosciences, Inc.
IDXG
$0.65
-$0.35-35.00%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.17% | 2.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.17% | 2.10% | |||
| Cost of Revenue | -29.02% | 3.86% | |||
| Gross Profit | 18.80% | 1.01% | |||
| SG&A Expenses | 4.63% | 7.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.03% | 6.18% | |||
| Operating Income | 61.26% | -15.60% | |||
| Income Before Tax | 109.96% | -36.17% | |||
| Income Tax Expenses | -300.00% | 0.00% | |||
| Earnings from Continuing Operations | 111.16% | -36.24% | |||
| Earnings from Discontinued Operations | 119.51% | -10.81% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 125.94% | -37.92% | |||
| EBIT | 61.26% | -15.60% | |||
| EBITDA | 59.07% | -14.33% | |||
| EPS Basic | 89.02% | -38.16% | |||
| Normalized Basic EPS | 109.26% | -36.42% | |||
| EPS Diluted | -83.60% | -38.14% | |||
| Normalized Diluted EPS | -81.35% | -36.49% | |||
| Average Basic Shares Outstanding | 0.34% | 0.39% | |||
| Average Diluted Shares Outstanding | 1,024.21% | 0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||